Etifoxine Hydrochloride - CAS 56776-32-0
Catalog number: 56776-32-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C17H18Cl2N2O
Molecular Weight:
337.24
COA:
Inquire
Targets:
GABA Receptor
Description:
Etifoxine Hydrochloride is Potentiator of GABAA receptor with anxiolytic and anticonvulsant activity.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
White Solid
Synonyms:
6-Chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine Hydrochloride; 2-Ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine Hydrochloride
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Psychotropic agent with anxiolytic and anticonvulsant activity
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Milligrams-Grams
Melting Point:
133-135 °C
InChIKey:
SCBJXEBIMVRTJE-UHFFFAOYSA-N
InChI:
1S/C17H17ClN2O.ClH/c1-3-19-16-20-15-10-9-13(18)11-14(15)17(2,21-16)12-7-5-4-6-8-12;/h4-11H,3H2,1-2H3,(H,19,20);1H
Canonical SMILES:
N1=C(O[C@@](c2c1ccc(c2)Cl)(c1ccccc1)C)NCC.Cl
Current Developer:
Anvyl
1.Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.
Stein DJ1. Adv Ther. 2015 Jan;32(1):57-68. doi: 10.1007/s12325-015-0176-6. Epub 2015 Jan 27.
BACKGROUND: Adjustment disorder with anxiety (ADWA) is a highly prevalent condition, particularly in primary care practice. There are relatively few systematic treatment trials in the area of ADWA, and there are few data on predictors of treatment response. Etifoxine is a promising agent insofar as it is not associated with dependence, but in primary care settings benzodiazepines continue to be frequently prescribed for psychiatric symptoms. A randomized controlled trial of etifoxine versus alprazolam for ADWA was undertaken, focusing on efficacy and safety measures, and including an investigation of predictors of clinical response.
2.A microPET comparison of the effects of etifoxine and diazepam on [(11)C]flumazenil uptake in rat brains.
Bouillot C1, Bonnefoi F1, Liger F1, Zimmer L2. Neurosci Lett. 2016 Jan 26;612:74-9. doi: 10.1016/j.neulet.2015.11.042. Epub 2015 Nov 28.
Using positron emission tomography (PET), the present study assessed the binding of [(11)C]flumazenil to GABA-A receptors in anesthetized rats following a single intravenous injection of an active dose of either etifoxine (25mg/kg) or diazepam (1mg/kg), which are both anxiolytic drugs. [(11)C]flumazenil binding was measured in five discrete brain structures, namely the caudate putamen, hippocampus, cerebellum, occipital cortex and parietal cortex. As expected, diazepam injection produced a significant decrease in [(11)C]flumazenil binding, which was interpreted as benzodiazepine GABA-A receptor occupancy, whereas etifoxine increased the binding of [(11)C]flumazenil. This first use of in vivo imaging after etifoxine administration revealed the activated binding pattern of [(11)C]flumazenil and highlighted the pharmacological differences between etifoxine and benzodiazepines. Using the same [(11)C]flumazenil radiotracer, PET neuroimaging could be applied to larger animals and, ultimately, to human subjects, thus providing new perspectives for better defining the molecular pharmacology of etifoxine.
3.The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.
do Rego JL1, Vaudry D2, Vaudry H2. PLoS One. 2015 Mar 18;10(3):e0120473. doi: 10.1371/journal.pone.0120473. eCollection 2015.
Neurosteroids can modulate the activity of the GABAA receptors, and thus affect anxiety-like behaviors. The non-benzodiazepine anxiolytic compound etifoxine has been shown to increase neurosteroid concentrations in brain tissue but the mode of action of etifoxine on neurosteroid formation has not yet been elucidated. In the present study, we have thus investigated the effect and the mechanism of action of etifoxine on neurosteroid biosynthesis using the frog hypothalamus as an experimental model. Exposure of frog hypothalamic explants to graded concentrations of etifoxine produced a dose-dependent increase in the biosynthesis of 17-hydroxypregnenolone, dehydroepiandrosterone, progesterone and tetrahydroprogesterone, associated with a decrease in the production of dihydroprogesterone. Time-course experiments revealed that a 15-min incubation of hypothalamic explants with etifoxine was sufficient to induce a robust increase in neurosteroid synthesis, suggesting that etifoxine activates steroidogenic enzymes at a post-translational level.
4.Characterization of the fast GABAergic inhibitory action of etifoxine during spinal nociceptive processing in male rats.
Juif PE1, Melchior M1, Poisbeau P2. Neuropharmacology. 2015 Apr;91:117-22. doi: 10.1016/j.neuropharm.2014.12.022. Epub 2014 Dec 26.
Etifoxine (EFX) is a non-benzodiazepine anxiolytic which potentiate GABAA receptor (GABAAR) function directly or indirectly via the production of 3α-reduced neurosteroids. The later effect is now recognized to account for the long-term reduction of pain symptoms in various neuropathic and inflammatory pain models. In the present study, we characterized the acute antinociceptive properties of EFX during spinal pain processing in naive and monoarthritic rats using in vivo electrophysiology. The topical application of EFX on lumbar spinal cord segment, at concentrations higher than 30 μM, reduced the excitability of wide dynamic range neurons receiving non-nociceptive and nociceptive inputs. Windup discharge resulting from the repetitive stimulation of the peripheral receptive field, and recognized as a short-term plastic process seen in central nociceptive sensitization, was significantly inhibited by EFX at these concentrations. In good agreement, mechanical nociceptive thresholds were also significantly increased following an acute intrathecal injection of EFX.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 73604-30-5 (-)-Bicuculline methobromide

(-)-Bicuculline methobromide
(CAS: 73604-30-5)

(-)-Bicuculline methobromide is the methobromide salt of (+)-bicuculline, which is a potent antagonist of GABAA receptors.

CAS 63701-55-3 Arbaclofen Hydrochloride

Arbaclofen Hydrochloride
(CAS: 63701-55-3)

Arbaclofen, the R-enantiomer of baclofen, is a selective gamma-amino butyric acid type B receptor agonist used for autism spectrum disorder and fragile X syndro...

CAS 3569-10-6 Valerenic acid

Valerenic acid
(CAS: 3569-10-6)

Valerenic acid is a positive allosteric modulator of GABAA receptors displaying selectivity for receptors containing β2 or β3 subunits. Valerenic acid exhibits ...

CAS 84454-35-3 β-CCB

β-CCB
(CAS: 84454-35-3)

β-CCB is an endogenous benzodiazepine binding inhibitor with proconvulsant and anxiogenic properties.

CAS 134516-99-7 U 90042

U 90042
(CAS: 134516-99-7)

U 90042 is a GABAA receptor ligand binding to three receptor subtypes: α1β2γ2, α3β2γ2 and α6β2γ2 (Ki = 7.8, 9.5 and 11.0 nM, respectively). U 90042 potentiates ...

CAS 155569-91-8 Emamectin Benzoate

Emamectin Benzoate
(CAS: 155569-91-8)

Emamectin Benzoate is the Emamectin derivative. Emamectin, also called as Proclaim, is widely used as an insecticide because of its chloride channel activation ...

CAS 1028141-88-9 RuBi-GABA

RuBi-GABA
(CAS: 1028141-88-9)

RuBi-GABA, a ruthenium-bipyridine-triphenylphosphine caged GABA, is a photolabile protecting group used for highly efficient visible light GABA uncaging.

CAS 184845-18-9 NNC 05-2090 hydrochloride

NNC 05-2090 hydrochloride
(CAS: 184845-18-9)

NNC052090 is a GABA uptake inhibitor that displays selectivity for BGT-1 (mGAT-2) transporters.

CAS 38090-53-8 TACA

TACA
(CAS: 38090-53-8)

TACA, the trans-isomer of CACA, is a potent GABAA and GABAC agonist, GABA uptake inhibitor and substrate for GABA-T. It also acts as a GABAA-ρ agonist.

CAS 371962-01-5 ZAPA sulfate

ZAPA sulfate
(CAS: 371962-01-5)

ZAPA sulfate acts as an agonist at low affinity GABAA receptors and is thus a useful ligand to investigate GABA receptors linked to benzodiazepine receptors. ZA...

CAS 1236105-75-1 PHP 501 trifluoroacetate

PHP 501 trifluoroacetate
(CAS: 1236105-75-1)

PHP 501 trifluoroacetate is potent GABAA antagonist (Ki = 0.0028 μM at rat GABAA receptors; IC50 = 0.024 μM at human α1β2γ2 GABAA-expressing tsA201 cells), with...

CAS 1134-47-0 Baclofen

Baclofen
(CAS: 1134-47-0)

Baclofen, an agonist of GABAB receptor, could be effective as a skeletal muscle relaxant and has been also found to have antispastic effect.

SCH-50911
(CAS: 733717-87-8)

CH-50911 is a selective GABA-B antagonist with IC50 value of 1.1 μM. It is developed by Schering-Plough Corporation. CH-50911 is often used in pharmacology rese...

CAS 56287-74-2 Afloqualone

Afloqualone
(CAS: 56287-74-2)

Afloqualone is a agonist of GABA receptor has sedative and muscle-relaxant effects.

CAS 66548-69-4 CL 218872

CL 218872
(CAS: 66548-69-4)

CL 218872 has been found to be a benzodiazepine agonist and has been found to exhibit anxiolytic and anticonvulsant activities.

CAS 927866-58-8 DPNI-caged-GABA

DPNI-caged-GABA
(CAS: 927866-58-8)

DPNI-caged-GABA, a kind of neurotransmitter, has been found to be allowed optical control of neural tissue with high spatial and temporal precision.

CAS 127729-35-5 SKF 97541

SKF 97541
(CAS: 127729-35-5)

SKF 97541 is a highly potent GABAB agonist, and also acts as a GABAA-ρ antagonist. SKF 97541 exhibits sedative effects in mammals and has the potential to be us...

CAS 164025-44-9 PZ-II-029

PZ-II-029
(CAS: 164025-44-9)

PZ-II-029,a pyrazoloquinolinone, was reported as the first postitive modulator of GABAA α6β3γ2 subtype functionally selective ligands to date.

CAS 40371-51-5 (S)-(-)-4-Amino-2-hydroxybutyric acid

(S)-(-)-4-Amino-2-hydroxybutyric acid
(CAS: 40371-51-5)

(S)-(-)-4-Amino-2-hydroxybutyric acid is an analogue of γ-aminobutyric acid (GABA) that exhibits potential inhibitory activity on GABA binding and uptake by bra...

CAS 628690-75-5 TP 003

TP 003
(CAS: 628690-75-5)

TP 003 is a selective GABAA receptor (α3 subtype) partial agonist with affinity for the benzodiazepine binding site on human GABAA receptors. TP 003 exhibits an...

Chemical Structure

CAS 56776-32-0 Etifoxine Hydrochloride

Quick Inquiry

Verification code

Featured Items